Utah Medical Products : Form 8-K Sec Filing - Form 8-K
November 01, 2022 at 02:30 pm EDT
Share
UTAH MEDICAL PRODUCTS, INC. - Form 8-K SEC filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): November 1, 2022
UTAH MEDICAL PRODUCTS, INC.
(Exact name of registrant as specified in its charter)
Utah
000-12575
87-0342734
(State or other jurisdiction of
(Commission File Number)
(IRS Employer
incorporation or organization)
Identification No.)
7043 South 300 West
Midvale, Utah
84047
(Address of principal executive offices)
(Zip code)
Registrant's telephone number, including area code:
Phone: (801) 566-1200
n/a
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (Section 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 8.01-OTHER EVENTS
On November 1, 2022, Utah Medical Products, Inc. announced that it is increasing its regular quarterly cash dividend. A dividend of $.295 per share is payable on January 4, 2023 to shareholders of record at the close of business on December 16, 2022. A copy of the press release is attached hereto as Exhibit 99.1.
ITEM 9.01-FINANCIAL STATEMENTS AND EXHIBITS
The following is filed as an exhibit to this report:
*All exhibits are numbered with the number preceding the decimal indicating the applicable SEC reference number in Item 601 and the number following the decimal indicating the sequence of the particular document.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
UTAH MEDICAL PRODUCTS, INC.
Dated: November 1, 2022
By:
/s/ Kevin L. Cornwell
Kevin L. Cornwell,
Chief Executive Officer
Attachments
Original Link
Original Document
Permalink
Disclaimer
Utah Medical Products Inc. published this content on 01 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 November 2022 18:29:02 UTC.
Utah Medical Products, Inc. is engaged in the business of producing medical services. The Company markets a range of medical devices used in critical care areas, especially the neonatal intensive care unit (NICU), the labor and delivery (L&D) department and the women's health center in hospitals, as well as medical devices sold to outpatient clinics and physician's offices. Its products include BT-CATH, CVX-RIPE, AROM-COT, MUC-X, CORDGUARD, DISPOSA-HOOD, DELTRAN PLUS, GESCO, PICC-NATE, LETZ System, Filshie Clip System, PATHFINDER PLUS, SUPRAPUBIC CATHETERIZATION, LIBERTY System, ENDOCURETTE, LUMIN, and BioPharm HP-PRT, among others. BT-CATH is a uterine balloon tamponade catheter for controlling severe postpartum hemorrhage. MUC-X is an aspiration device used immediately after birth to clear neonatal respiratory passages and reduce exposure to potential infections. AROM-CO is a finger cover with a prong designed to rupture maternal membranes with less patient pain and anxiety.